Fundraising Fox
Modulate Bio
Allston, US · Founded 2023 · Delaware corporation · 4 employees on LinkedIn · 3 known investors
Find your way into Modulate Bio
Sign up to see every warm intro you have to Modulate Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Modulate Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Modulate Bio develops small-molecule GABAA positive allosteric modulators to treat neurological disorders including Essential Tremor, epilepsy, and anxiety. Its drug-discovery platform aims to selectively activate specific GABAA receptor subunits to provide efficacy while limiting side effects.
Founders & leadership
Modulate Bio was founded in 2023 by Dario Doller and Kevin Hodgetts.
DD
Dario DollerCo-founder · Chief Scientific Officer (CSO)Dario Doller is a medicinal chemist with 30 years of experience in pharmaceutical drug discovery across CNS targets. He has contributed to the development of Vorapaxar and four additional FDA-approved or clinical-stage drugs, and co-edited two volumes on allosterism and CNS drug discovery.
MB
Mitchell Buckley
Investors · 3
Pillar VC✓ confirmed by Modulate BioBoston · $50K – $4M
How we know: the company's own site · Not right? Tell us
Palo Santo VClisted by Palo Santo VC
How we know: Palo Santo VC's portfolio page · Not right? Tell us
Healthspan CapitalreportedOxford · $5K
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$785.3K disclosed across 1 round · 2024
▶$785.3KraisedApr 2026 · 10 investors · BiotechnologyRule 506(b)
▶$785.3KraisedApr 2026 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin HodgettsPromoter
- Dario DollerExecutive Officer, Director, Promoter
- Andrew ThomsonExecutive Officer, Director, Promoter
- Offering amount
- $1M
- Amount sold
- $785.3K
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
Liberate BioLiberate Bio develops lipid nanoparticle (LNP) delivery technologies for in vivo cell therapies and genetic medicines, with a focus on myeloid-optimized CAR-M programs that target tissues beyond the liver. The company works on targeted nucleic acid delivery for therapeutic applications.
ModulightModulight develops a platform to treat severe neurological diseases through scientific innovation and clinical expertise.
Emulate BioEmulate builds Organ-on-a-Chip systems, including platforms, consumables, and pre-assembled BioKits with validated human cell models, to support drug discovery research. It serves life sciences and pharmaceutical researchers and provides installation, training, and validated protocols for Organ-Chip experiments.
CreateCREATE Medicines is a clinical-stage biotech company that develops in vivo mRNA immune cell programming therapies. The company focuses on RNA therapeutics and immune engineering for cancer, autoimmune disease, and transplant rejection applications.
Modulari-TModulari-T develops proprietary cell therapy technologies, including the MARC receptor and MoVe platform, based on primary research into immune system architecture. The company serves the cell therapy and immunotherapy market.
Applied TherapeuticsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Modulo BioModulo is a biotech company focused on the neuroimmune system, developing treatments for brain and central nervous system disorders. It uses multiple neurobiology models and computational biology to study neuroimmune mechanisms and discover new therapies for patients affected by neurological disease.
Companies working in the same space as Modulate Bio.
Frequently asked questions
- What does Modulate Bio do?
- Modulate Bio develops small-molecule GABAA positive allosteric modulators to treat neurological disorders including Essential Tremor, epilepsy, and anxiety. Its drug-discovery platform aims to selectively activate specific GABAA receptor subunits to provide efficacy while limiting side effects.
- Who founded Modulate Bio?
- Modulate Bio was founded by Dario Doller, Kevin Hodgetts in 2023.
- Who are Modulate Bio's investors?
- Modulate Bio's investors include Pillar VC, Palo Santo VC, Healthspan Capital.
- How much funding has Modulate Bio raised?
- Modulate Bio has disclosed $785.3K raised across 1 round.
- Where is Modulate Bio headquartered?
- Modulate Bio is headquartered in Allston, US.